# Efficacy of praziquantel against urinary schistosomiasis and reinfection in Senegalese school children where there is a single well-defined transmission period

Bruno Senghor, Omar Talla Diaw, Souleymane Doucoure, Seydou Nourou

Sylla, Mouhamadane Seye, Idrissa Talla, Cheikh Tidiane Bâ, Adiouma Diallo, Cheikh Sokhna

► To cite this version:

Bruno Senghor, Omar Talla Diaw, Souleymane Doucoure, Seydou Nourou Sylla, Mouhamadane Seye, et al.. Efficacy of praziquantel against urinary schistosomiasis and reinfection in Senegalese school children where there is a single well-defined transmission period. Parasites & Vectors, 2015, 8 (1), 10.1186/s13071-015-0980-5. [https://doi.org/10.1186/s13071-015-0980-5](https://doi.org/10.1186/s13071-015-0980-5). [hal-04087769](https://hal.science/hal-04087769)

HAL Id: hal-04087769

https://hal.science/hal-04087769

Submitted on 19 Oct 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>
<figure><img src="image_2.png" /></figure>

Efficacy of praziquantel against urinary
schistosomiasis and reinfection in
Senegalese school children where there is
a single well-defined transmission period

Bruno Senghor<fnref n="1" />,², Omar Talla Diaw⁴, Souleymane Doucoure<fnref n="1" />, Seydou Nourou Sylla<fnref n="1" />,³, Mouhamadane Seye⁴, Idrissa Talla⁵, Cheikh Tidiane Bâ², Adiouma Diallo<fnref n="1" /> and Cheikh Sokhna<fnref n="1" />*

**Abstract**

**Background:** Human schistosomiasis is a significant health problem in Sub-Saharan Africa. In Niakhar, West central Senegal, the transmission of *S. haematobium* occurs seasonally between July and November. No control measures have been implemented despite high prevalence reported in previous studies. This aim of this study was to i) determine the current prevalence of *S. haematobium* in children at Niakhar, ii) assess the efficacy of one dose of PZQ (40 mg/kg) against *S. haematobium* and iii) monitor reinfection.

**Methods:** The current study was carried out in a cohort of 329 children aged five to 15 years enrolled from six villages in Niakhar to determine the efficacy of one dose of PZQ, as well as reinfection. Parasitological screening was performed in June 2011 to determine the baseline prevalence of *S. haematobium*, and then a single dose of PZQ was administered to all selected subjects in the transmission season in August 2011. The efficacy of PZQ treatment and reinfection were monitored respectively five weeks after in September 2011 and from February to March 2012.

**Results:** At baseline, the overall prevalence and the heavy intensity of infection were 73.2 % and 356.1 eggs/10 ml of urine. Significant differences in the prevalence and intensity of *S. haematobium* infection were noted between villages. A single dose of PZQ significantly reduced the prevalence of *S. haematobium* infection from 73.2 % to 4.6 % and the geometric mean intensity of infection from 356.1 to 43.3 eggs/10 ml of urine. The cure rates ranged from 89.4 % to 100 %. The egg reduction rates also ranged from 77.6 % to 100 %. Two to three months after the period of transmission, the overall rate of reinfection was 12.6 % and was significantly higher in male children than in female children. The overall prevalence at this period was 13.8 %, which was significantly lower than the prevalence at baseline (73.2 %).

**Conclusion:** The Niakhar study area remains a hot spot of urinary schistosomiasis in Senegal with differences in transmission between villages. This study suggests that when transmission is strictly seasonal, Praziquantel shows the expected efficacy in reducing the prevalence and intensity of infection, but also a significant effect on the occurrence of reinfection.

**Keywords:** Urinary schistosomiasis, Seasonal transmission, Praziquantel treatment, Reinfection, Niakhar, Senegal

<footnote>* Correspondence: cheikh.sokhna@ird.fr</footnote>

<footnote n="1">¹Institut de Recherche pour le Développement, UMR 198 (URMITE), Campus International de Hann, IRD, BP 1386, Dakar CP 18524, Sénégal
Full list of author information is available at the end of the article</footnote>
## Background

Human schistosomiasis remains a significant public health issue worldwide [1]. Sub-Saharan Africa is the most affected region, encompassing 90 % of the 207 million schistosomiasis cases recorded in the world [1, 2]. The burden of schistosomiasis is exacerbated in low income countries where access to clean water and regular sanitation systems is limited [3, 4]. The disease is caused by six *Schistosoma* species: *S. haematobium*, *mansoni*, *japonicum*, *intercalatum*, *mekongi* and *guineensis* [5, 6].

In sub-Saharan Africa, *S. haematobium* and *S. mansoni* are the predominant species causing urogenital and intestinal schistosomiasis, respectively [5, 6]. In areas with permanent water bodies, these two species can be co-endemic [7]. By contrast, *S. haematobium* is only transmitted in seasonal transmission areas, due to the fact that only the snail of the genus *Bulinus*, the intermediate hosts, can resist aestivation during the dry time of year, unlike the snails of genus *Biomphalaria*, the intermediate host of *S. mansoni* [8, 9].

Currently, in endemic areas, the control of schistosomiasis disease is mainly based on chemo-preventative strategies to prevent morbidity later in life due to the chronic infection with *Schistosoma* parasites. School-aged children and communities at high risk of infection are targeted. The treatment consists of a single oral dose of 40 mg/kg Praziquantel (PZQ) after or without a prior diagnosis of *Schistosoma* spp. [3, 10]. PZQ is also the drug of choice for the treatment of schistosomiasis due to its high efficacy against all schistosome species infecting humans [11].

The implementation in the past 10 years of national control programs based on mass PZQ administration in school-age children, has allowed the significant reduction in transmission of schistosomiasis in Sub-Saharan Africa [10]. Despite a few reports of treatment failures [12, 13], the majority of studies showed good efficacy of PZQ, with high egg reduction rates (ERRs) in the urine in foci of intense *S. haematobium* transmission and especially in low-to-moderate transmission areas where the risk of reinfection is generally low [14–16].

The rate and intensity of post-PZQ chemotherapy reinfection varies between schistosome species, the dynamic of the transmission and the level of endemicity [15]. In areas of permanent schistosomiasis transmission, the efficacy of the treatment is enhanced when PZQ is administered when the level of disease transmission is low [17]. In southwestern Niger, the effectiveness of treatment with a single dose of PZQ was better in the village located along a temporary pond than in the village near an irrigated area of the Niger River Valley where the transmission is permanent [18].

In Senegal, *S. haematobium* and *S. mansoni* coexist in 3 regions: the region of the Senegal River Basin (SRB)

[19], Kolda [20] and Kedougou [21], respectively in the north, south and south east of the country. The disease is most prevalent along the Senegal River Basin where the prevalence can reach 95 % due to the permanence of transmission, since contact with water is inevitable [7].

In these villages around the SRB and the “lac de Guiers”, several previous studies evaluated the efficacy of one or repeated treatments and monitored the reinfection rates. The results showed a high efficacy of PZQ against *S. haematobium* infections but reinfection occurred rapidly and the prevalence could reach the pre-treatment level [7, 22, 23]. This makes it difficult to control and eliminate the disease in this region despite the many efforts following the outbreak of Richard-Toll [24]. These are the reasons that new approaches to biological control of schistosomiasis are under experimentation in the SRB [25, 26].

By contrast, most parts of the country, except the region of Dakar (the capital), only *S. haematobium* is endemic in the ten other regions and the disease is most prevalent in school-age children [27]. In these regions, the prevalence of urinary schistosomiasis is increasing because of the absence of regular treatments, the opposite of what is happening in the SRB. No information is available on the efficacy of PZQ against *S. haematobium* and reinfection after treatment in these settings where the disease occurs seasonally in temporal ponds and/or backwaters during the rainy season in Senegal. This is the case in the Fatick region, where in 1996, the prevalence ranged from 3 % to 31 % in some villages of the region [27]. In other parts of the region, more recent studies have shown an increased prevalence of up to 39.6 % in 2007 [28] and more than 50 % in 2009 [29].

In the Niakhar area, in central Senegal, the hydro geographical system is only constituted by temporary ponds and backwaters. *S. haematobium* transmission occurs seasonally between July and November with high prevalence and intensity of infection [29]. The population of Niakhar has no access to PZQ and until now, no mass drug administration against *S. haematobium* has been performed. The aims of the present longitudinal study were to assess the efficacy of PZQ-based treatment against *S. haematobium* and to monitor reinfection in Niakhar school-age children.

## Methods

### Study area

The study was carried out at Niakhar district (14°30 N, 16°30 W), a demographic survey site located in the region of Fatick (West central Senegal), 135 km east of Dakar, the capital of Senegal, in West Africa. The rainy season spans four months (July through October) [30]. The area is a seasonal transmission focus of urinary schistosomiasis. *S. haematobium* transmission sites consisted
of only ponds and backwaters that were made from July to December. In the middle of winter, the area is separated from south to north by the backwater that persists during the dry season. The ponds dry up faster than the backwaters. From January until the end of June, the population of Niakhar is not exposed to *S. haematobium*, as all water collections are dry. The study population included school-age children between 5 and 15 years of age enrolled from six villages of Niakhar: Gajak, Godel, Logdir, Sass njafaj, Ngalagne kop and Puday. In the villages of Gajak and Godel the backwaters are used especially for bathing, swimming, laundry, fetching water, washing pets and fishing while in Sass njafaj, Ngalagne kop, Puday and Logdir those activities are done in the ponds, except fishing. Geographical positions of the main water points and the houses selected in each village surveyed were determined using a global positioning system (GPS). The hydrological network varies from village to village. It is very dense at Ngalagne kop, Puday and Logdir where the ponds are near the houses. At Sass njafaj ponds are rare and far from the houses. The same situation is observed at Godel where the populations use one pond, but which is near the houses. At Gajak, there is no pond but the village is bordered by a large backwater near the houses (Fig. 1). There was no mass PZQ administration before the study. A more detailed description of the Niakhar study area has been given elsewhere [29, 31].

## Treatment

Praziquantel was given by Merck KGaA; Darmstadt, Germany to the World Health Organization (WHO) for mass distribution by the national program in the fight against schistosomiasis in Senegal. The Niakhar study area is one of the sites selected for five rounds of annual mass treatment against schistosomiasis based on the prevalence of urinary schistosomiasis higher than 50 % [29]. This study took place a year before the beginning of mass treatments in the study zone. The drug was made available to us by the national program and was administered at the standard dose of 40 mg/kg at the health centers of the study zone, and in the presence of a nurse and an agent from the national program.

## Study design

This study is a longitudinal cohort survey before and after treatment with PZQ. The six villages were enrolled based on their *S. haematobium* prevalence reported in a previous study [29]. The study was conducted between June 2011 and March 2012. The inclusion criteria were: i) residence in the studied villages during the rainy season, ii) an age of between 5 and 15 years and iii) consent to participate in the study. At the beginning of the study, in June 2011, the population of study was not in contact with water collections because the Niakhar area was dry

from December 2010 to June 2011. The study was conducted in three successive phases with the same children surveyed at each point of time (Fig. 2):

- Study of the baseline prevalence of *S. haematobium* in Niakhar: this phase was conducted in June 2011, before the beginning of the 2011 transmission season. At these points in time, a baseline urine examination was conducted in all children selected for the study. A child is considered infected by *S. haematobium* if at least one egg is found in a urine sample during microscopic observation.

- Monitoring the efficacy of PZQ treatment: in early August 2011, after the baseline phase, PZQ (40 mg/kg) was administered to all children selected, whether infected or not. The treatment was done in the middle of the transmission season because PZQ was not available between June and July. Five weeks after treatment, in September 2011, one urine sample was collected from each child to assess the efficacy of the treatment. Any individual was considered cured if no egg was found in the urine sample examined.

- Monitoring reinfection: reinfection was monitored from February to March 2012 when all water collections are totally dry and *S. haematobium* transmission does not occur. Urine samples were collected to determine the rate of reinfection. This monitoring of reinfection involved only children who were positive and subsequently became negative and then positive again. Each negative individual during the September 2011 survey of PZQ treatment efficacy was considered reinfected if at least one egg was found in the urine sample.

## Urine Sample collection and microscopic analysis for the detection of *S. haematobium* eggs

Urine samples were collected door-to-door between 10:00 am and 2 p.m., and transferred to the Niakhar laboratory for parasitological analysis during the same day. The urine sample was shaken to ensure the dispersal of eggs and then ten milliliters were taken and filtered through a Millipore® SX0001300 Swinnex® Syringe Filter. Filtration was followed by microscopic examination for detection of *S. haematobium* eggs according to the method developed by Plouvier *et al.* [32]. The infection intensity was classified as light (1–49 eggs/10 ml of urine) or heavy (≥50 eggs/10 ml of urine), as defined by the World Health Organization [33].

## Ethical approval

The study was part of a larger investigation on schistosomiasis epidemiology, transmission and control in Senegal and which was approved by the Senegalese National Ethics
<figure><img src="image_3.png" /><figcaption>**Fig. 1** Map of the Niakhar study area showing the water points and the houses in the villages investigated</figcaption></figure>
<figure><img src="image_4.png" /><figcaption>**Fig. 2** Study design</figcaption></figure>

Committee (reference No.SN11/57). The objectives of the study were explained to the children and to their parents or legal guardians, from whom written informed consent was obtained.

## Statistical analysis

Data from each village were recorded using Epi-Info, version 3.5.1 and analyzed using STATA 11.1. The relationships between characteristics of *S. haematobium* infection (prevalence, intensity and reinfection) and other variables, such as the location of villages and the sex and age of children, were tested at baseline. Prevalence comparisons were performed using the chi-squared test and Fisher's exact modification of the 2 × 2 chi-squared test [34]. For infection intensity values, the Geometric Means of Williams was used to calculate the Geometric Eggs Mean Count (GEMC) in only positive individuals. PZQ efficacy was measured by determining both cure rate (CR) and egg reduction rate (ERR). The CR is the percentage of children positive for egg-patent infection becoming negative after treatment. The ERR is the percentage reduction in GEMC, as measured by *S. haematobium* eggs, after drug treatment of children with egg-patent infections at baseline. The ERR was calculated as [1 - (GEMC after treatment/ GEMC before treatment)] × 100 [35]. GEMC among different groups was compared using ANOVA. In all case, a P-value < 0.05 was taken to indicate statistical significances.

## Results

### Baseline prevalence and intensity of *S. haematobium* infection by village, sex and age

Six villages Gajak, Godel, Logdir, Ngalagne, Puday and Sass njafaj were selected for the study. A total of 329 subjects were enrolled at baseline. The average age and the sex ratio m/f were 8.8 (SD, 3.1) years and 1.4, respectively. The population was arbitrarily classified into three age groups: 5 to 7, 8 to 10 and 11 to 15 years. Table 1 summarizes the demographic characteristics of the cohort.

Among the 329 individuals examined at baseline, 241 (73.2 %) were infected by *S. haematobium* and the other

88 were negative (Table 2). The prevalence of *S. haematobium* infection was 92.3 %, 80.5 %, 78.8 %, 71.4 %, 61.5 % and 50 % at Ngalagne kop, Logdir, Gajak, Poudaye, Godel and Sass njafaj, respectively. The GEMC varied from 1573.9 eggs/10 ml of urine in the village of Ngalagne kop to 128.3 eggs/10 ml of urine in Logdir. Significant differences in the prevalence and intensity of infection were noted between villages (*p* < 0.001). The infection rate was higher in males (80.2 %) than females (64.1 %) (*p* < 0.05). The same trend was observed with the GEMC, which was 544.1 and 177.0 eggs/10 ml of urine for males and females, respectively. Significant differences in prevalence and GEMC according to sex were noted (*p* < 0.05) (Table 3). Prevalence increased according to age with 62.4 %, 80.9 % and 81.9 % in the 5 to 7, 8 to 10 and 11 to 15 age groups, respectively. But the GEMC was higher in the 8 to 10 year age group. Significant differences in the prevalence and intensity of infection were noted between the 5 to 7 year age group and the others (*p* < 0.001) (Table 3).

### Efficacy of PZQ against *S. haematobium* according to village, sex and age

Among the 241 infected children, 237 were treated and monitored for PZQ efficacy. Four children were not treated due to their absence and are excluded in the study but they were referred to health centers where the rest of PZQ was left. A total of 222 children were egg negative after treatment. The overall CR and ERRs were 93.7 % and 87.8 %, respectively. After treatment, the overall prevalence and the GEMC were significantly reduced. The prevalence of *S. haematobium* infection decreased from 73.2 % to 4.6 % (*p* < 0.05). Significant decreases in prevalence were noted in each village (*p* < 0.05). Prevalence after PZQ treatment was 9.8 %, 7.3 %, 2.3 %, 2 %, 1.9 % and 0 %, in the villages of Ngalagne kop, Gajak, Sass njafaj, Godel, Puday and Logdir, respectively. The same trend was observed with the intensity of infection. The GEMC decreased from 356.1 to 43.3 eggs/10 ml of urine (*p* < 0.05). CRs were high in all six villages and varied from 89.4 % at Ngalagne kop to 100 % at Logdir. The ERRs were also high and ranged
<table><caption>**Table 1** Demographic characteristics of the studied population</caption><thead><tr><th>Villages</th><th>Sample size at baseline</th><th>Age mean (SD<sup>a</sup>) in years</th><th>Sex ratio (M/F)</th></tr></thead><tbody><tr><td>Gajak</td><td>98</td><td>7.8 (2.6)</td><td>0.8</td></tr><tr><td>Godel</td><td>52</td><td>8.2 (2.8)</td><td>0.8</td></tr><tr><td>Logdir</td><td>31</td><td>8.5 (3.2)</td><td>0.6</td></tr><tr><td>Ngalagne kop</td><td>52</td><td>9.1 (2.8)</td><td>1.5</td></tr><tr><td>Puday</td><td>52</td><td>8.3 (3)</td><td>1.5</td></tr><tr><td>Sass ndiafaj</td><td>44</td><td>9.5 (2.7)</td><td>1.3</td></tr><tr><td>Total</td><td>329</td><td>8.8 (3.1)</td><td>1.4</td></tr></tbody></table>

<sup>a</sup>Standard Deviation

from 77.6 % to 100 % in these same villages. No significant difference was observed in the CR and ERRs between villages (p > 0.05) (Table 2).

In the 237 positive children treated, 222 were totally cured and eggs were found in urine samples of only 15 (6.3 %) children. Among these 15 children at baseline, five had excreted over 49 eggs/10 ml of urine and three of them lived in the village of Ngalagne kop where the highest GEMC (1 573.9 eggs/10 ml of urine) was recorded during this study.

The efficacy of PZQ against *S. haematobium* infection based on age is shown in Table 3. After treatment, a significant reduction in the prevalence was observed. In each age group, pre-treatment prevalence was significantly reduced from 62.4 % to 4.2 %, 80.9 % to 7.7 % and 81.9 % to 1.2 % in the 5 to 7, 8 to 10 and 11 to 15 age groups, respectively (p < 0.05). The highest CR (96.9 %) and ERR (94.3 %) were recorded in the 11 to 15 age group. These parameters were lowest in the 8 to 10 year age group and were at 91.7 % and 85.3 % for the CR and ERRs, respectively. But there was no significant difference in the CR between age groups (p < 0.05). The results broken out by sex are also available in Table 3.

### Reinfection by villages, sex and age

The study of reinfection involved the 222 children who were cured after PZQ administration. Among these children who were negative after control of the treatment in September 2011, 28 (12.6 %) reinfection cases from the 2011 transmission season were detected from February to March 2012. The overall prevalence in the population at this point in time was 13.8 (Table 2). No reinfection occurred in the village of Sass where the lowest baseline prevalence was recorded. In the other villages, reinfection rates were 37.1 %, 11.9 %, 10.3 %, 8 % and 3.2 %, at Puday, Ngalagne kop, Gajak, Logdir and Godel, respectively. The patterns of reinfection with *S. haematobium* showed statistical difference between villages (p < 0.001). Compared to the baseline, in each village, the prevalence was significantly lower after the period of reinfection (p < 0.05). The overall GEMC (48.3 eggs/10 ml of urine)

was significantly lower than the baseline (356.1 eggs/ 10 ml) (p < 0.001) (Table 2). The reinfection rate was significantly higher in males (12.7 %) than in females (5.7 %) (p < 0.05). The reinfection rate was more significant in children aged 5 to 7 years (17.1 %) than in the groups of 8 to 10 and 11 to 15 which had quite quantitative statement reinfection rates: 10.5 % and 9.4 %, respectively. However, there was no significant difference in *S. haematobium* reinfection between the different age groups (p > 0.05) (Table 3).

### Discussion

In the present study, high prevalence and GEMC of *S. haematobium* infection are observed at baseline in the area of Niakhar. These results are in line with a recent investigation that has shown high prevalence and intensity of *S. haematobium* infection in the Niakhar district [29]. This high level of infection also confirms that Niakhar is a hot spot for *S. haematobium* transmission in Senegal. In endemic areas, the level of *S. haematobium* transmission is very significant in school-age children between 5 and 15 years of age [36]; this may explain the high prevalence noted in this study, which targeted only school-age children. This epidemiological situation in Niakhar, marked by a high level of urinary schistosomiasis transmission is also attributable to the lack of health education, poor sanitation and also the lack of safe water resulting in permanent contact with ponds and backwaters which are the main areas of *S. haematobium* transmission during the rainy season. In addition, before this investigation, no strategy, i.e. PZQ mass administration, has been implemented to control the transmission of the disease [14].

In this study, a high prevalence of *S. haematobium* was noted in all the study areas; however, the level of infection was heterogeneous between villages. The distribution of ponds and backwaters may result in heterogeneity in the prevalence and intensity of *S. haematobium* infections between study sites. This may have implications for the heterogeneity found in the transmission of the disease in Niakhar, where the highest level of *S. haematobium* infection was recorded in villages with the highest density of ponds and backwaters which are near the households like at Ngalagne kop, Logdir, Gajak, Puday. The lowest level of transmission is found in Sass njafaj, which has a poor pond system with limited frequentation by the population. Therefore, the results of this study indicate once again the importance of the hydrogeographical network in the epidemiology and transmission of *S. haematobium* [37, 38]. This heterogeneity between villages may also be explained by access to tap water present in some households in Niakhar, or by social behavior [29]. In the Niakhar study area, it has been shown that the level of frequentation of ponds and
<table><caption>**Table 2** The prevalence and intensity of *S. haematobium* infections in children from six villages in the Niakhar study area in Central Senegal before treatment with PZQ, 5 weeks post treatment and reinfection levels at 2 to 3 months after draining of ponds and backwater</caption><thead><tr><th colspan="9">Characteristics S. haematobium infection</th></tr><tr><th>Villages</th><th>Gajak</th><th>Godel</th><th>Logdir</th><th>Puday</th><th>Ngalagne kop</th><th>Sass njafaj</th><th>Total</th><th>P-value</th></tr></thead><tbody><tr><td colspan="9">Baseline (June 2011)</td></tr><tr><td>No. of children infected/examined</td><td>77/98</td><td>32/52</td><td>25/31</td><td>37/52</td><td>48/52</td><td>22/44</td><td>241/329</td><td>&lt;0.001</td></tr><tr><td>Prevalence (95 % CI)</td><td>78.6 % (67.2-83.8)</td><td>61.5 % (47.9-73.5)</td><td>80.6 % (63.7-90.8)</td><td>71.1 % (57.7-81.6)</td><td>92.3 % (81.8-96.9)</td><td>50 % (35.8-64.2)</td><td>73.2 % (68.2-77.2)</td><td></td></tr><tr><td>Numbers of infected children treated with PZQ</td><td>75</td><td>32</td><td>25</td><td>36</td><td>47</td><td>22</td><td>237</td><td></td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>169.8 (119.2-241.8)</td><td>189.3 (105.6-339.4)</td><td>128.3 (73.8-222.8)</td><td>966.6 (581.2-1607.5)</td><td>1573.9 (1208.2-2050.4)</td><td>276.8 (132.2-580.1)</td><td>356.1 (286.1-443.3)</td><td>&lt;0.001</td></tr><tr><td colspan="9">Treatment (August 2011)</td></tr><tr><td colspan="9">Follow-up efficacy of PZQ 5 weeks post treatment (in September 2011)</td></tr><tr><td>No. of children infected/examined</td><td>7/96</td><td>1/52</td><td>0/31</td><td>1/51</td><td>5/51</td><td>1/44</td><td>15/325</td><td></td></tr><tr><td>Prevalence (95 % CI)</td><td>7.3 % (3.6-14.3)</td><td>2 % (0.3-10.3)</td><td>0 % (0-11)</td><td>1.9 % (0.3-10.1)</td><td>9.8 % (4.2-20.6)</td><td>2.3 % (0.4-11.8)</td><td>4.6 % (2.7-7.4)</td><td>0.219</td></tr><tr><td>Numbers of infected treated examined</td><td>75</td><td>32</td><td>25</td><td>36</td><td>47</td><td>22</td><td>237</td><td></td></tr><tr><td>No of children cured (CR in %)</td><td>68 (90.6 %)</td><td>31 (96.8 %)</td><td>25 (100 %)</td><td>35 (97.2 %)</td><td>42 (89.4 %)</td><td>21 (95.4 %)</td><td>222 (93.7 %)</td><td>0.7</td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>38.1 (9.1-159)</td><td>30.0</td><td></td><td>35.0</td><td>64.9 (25.2-167.6)</td><td>25.0</td><td>43.3 (23.1-81.2)</td><td>0.144</td></tr><tr><td>ERR in %</td><td>77.6 %</td><td>84.1 %</td><td>100 %</td><td>96.4 %</td><td>95.9 %</td><td>90.9 %</td><td>87.8 %</td><td>0.92</td></tr><tr><td colspan="9">Reinfection after treatment (September to November 2011)</td></tr><tr><td colspan="9">Follow-up reinfection 2 to 3 months after transmission period in February and March 2012</td></tr><tr><td>No. of children infected/examined</td><td>15/96</td><td>2/52</td><td>2/31</td><td>14/51</td><td>11/51</td><td>1/44</td><td>45/325</td><td></td></tr><tr><td>Prevalence (95 % CI)</td><td>15.6 % (9.7-24.2)</td><td>3.8 % (1.1-12.9)</td><td>6.4 % (1.8-20.2)</td><td>26.9 % (16.7-40.2)</td><td>21.7 % (12.5-34.6)</td><td>2.3 % (0.4-11.8)</td><td>13.8 % (10.5-18)</td><td>0.002</td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>99.9 (45.1-221.3)</td><td>215.6 (0-11e + 13)</td><td>462.5 (0-5.7e + 11)</td><td>30.7 (10-94.5)</td><td>12.0 (4.4-33.1)</td><td>506.0</td><td>48.1 (26.6-86.8)</td><td>0.01</td></tr><tr><td>No. of children re-infected/surveyed</td><td>8/89</td><td>1/51</td><td>2/31</td><td>13/50</td><td>6/46</td><td>0/43</td><td>30/310</td><td></td></tr><tr><td>Reinfection rate (95 % CI)</td><td>8.9 % (4.6-16.7)</td><td>1.9 % (0.3-10.3)</td><td>6.4 % (1.7-20.7)</td><td>26 % (15.8-39.5)</td><td>12.8 % (5.9-25.2)</td><td>0 % (0.0-10)</td><td>9.7 % (6.9-13.5)</td><td>&lt;0.001</td></tr></tbody></table>
<table><caption>**Table 3** The prevalence and intensity of *Schistosoma haematobium* infections in children from six villages in the Niakhar study area in Central Senegal at baseline, 5 weeks post treatment and reinfection levels at 2 to 3 months after draining of ponds and backwater, relative to gender and age</caption><caption>Characteristics S. haematobium infection</caption><thead><tr><th>Variables</th><th>Female</th><th>Gender<br>Male</th><th>P-value</th><th>5 - 7 years</th><th>Age<br>8 - 10 years</th><th>11 - 15 years</th><th>P-value</th></tr></thead><tbody><tr><td>Baseline (June 2011)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of children infected/examined</td><td>91/142</td><td>150/187</td><td></td><td>88/141</td><td>85/105</td><td>68/83</td><td></td></tr><tr><td>Prevalence (95 % CI)</td><td>64.1 % (55.9-71.5)</td><td>80.2 % (73.9-85.3)</td><td>0.001</td><td>62.4 % (54.2-69.9)</td><td>80.9 % (72.4-87.3)</td><td>81.9 % (62.3-88.7)</td><td>0.001</td></tr><tr><td>Numbers of infected subject treated with PZQ</td><td>91</td><td>146</td><td></td><td>88</td><td>83</td><td>66</td><td></td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>177.0 (123.4-253.8)</td><td>544.1 (421.4-702.6)</td><td>0.001</td><td>238.9 (164.4-347.3)</td><td>455.6 (313-662.9)</td><td>438.7 (299.1-643.3)</td><td>&lt;0.001</td></tr><tr><td>Treatment (August 2011)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Follow-up efficacy of PZQ 5 weeks post<br>treatment (in September 2011)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of children infected/examined</td><td>3/142</td><td>12/183</td><td></td><td>6/141</td><td>8/103</td><td>1/81</td><td></td></tr><tr><td>Prevalence (95 % CI)</td><td>2.1 % (0.7-6)</td><td>6.5 % (3.7-10.9)</td><td>0.080</td><td>4.2 % (1.9-8.9)</td><td>7.7 % (3.9-14.4)</td><td>1.2 % (0.2-6.7)</td><td>0.200</td></tr><tr><td>No. of infected treated examined</td><td>91</td><td>146</td><td></td><td>88</td><td>83</td><td>66</td><td></td></tr><tr><td>No. of children cured (CR in %)</td><td>88 (96.7 %)</td><td>134 (91.8 %)</td><td>0.7</td><td>82 (93.2 %)</td><td>76 (91.7 %)</td><td>64 (96.9 %)</td><td>0.5</td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>15.7 (3.7-65.4)</td><td>55.8 (25.5-112.9)</td><td>0.06</td><td>26.5 (8-87.7)</td><td>67.0 (26.9-166.5)</td><td>25.0</td><td>0.109</td></tr><tr><td>ERR in %</td><td>91.1 %</td><td>89.7 %</td><td>0.99</td><td>88.9 %</td><td>85.3 %</td><td>94.3 %</td><td>0.99</td></tr><tr><td>Reinfection after treatment<br>(September to November 2011)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Follow-up reinfection 2 to 3 months after<br>transmission period in February and<br>March 2012</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of children infected/examined</td><td>11/142</td><td>34/183</td><td></td><td>22/141</td><td>14/103</td><td>9/81</td><td></td></tr><tr><td>Prevalence (95 % CI)</td><td>7.7 % (4.3-13.3)</td><td>18.6 % (13.1-24.8)</td><td>0.010</td><td>15.6 % (10.5-22.5)</td><td>13.6 % (8.2-21.5)</td><td>11.1 % (5.9-19.8)</td><td>0.486</td></tr><tr><td>GM egg count/10 ml of urine (95 % CI)</td><td>37.4 (37.4-12.38)</td><td>52.4 (25.2-109.2)</td><td>0.012</td><td>73.1 (31.8-168.3)</td><td>27.8 (9.4-82.4)</td><td>38.6 (5.6-263.7)</td><td>0.307</td></tr><tr><td>No. of children re-infected/surveyed</td><td>8/139</td><td>22/173</td><td></td><td>16/135</td><td>8/96</td><td>6/81</td><td></td></tr><tr><td>Reinfection rate (95 % CI)</td><td>5.7 % (2.9-10.9)</td><td>12.7 % (8.5-18.5)</td><td>0.001</td><td>11.8 % (7.4-18.4)</td><td>8.3 % (4.3-15.6)</td><td>7.4 % (3.4-15.2)</td><td>0.400</td></tr></tbody></table>
backwaters is strongly linked to social behavior and that contact with these water collections is more significant in male children, particularly those between 8 and 12 years of age [29]. Therefore, this could explain the difference in infection observed in male children compared to females and the highest prevalence in boys between the 8 to 10 and 11 to 15 years age groups. This situation in Niakhar required implementation PZQ mass administration targeting each year children aged 5 to 15 years and also health education to reduce contact with infested water.

Until now, the efficacy of control strategies based on PZQ mass administration is poorly documented in seasonally *S. haematobium* transmission foci in Senegal. This study revealed that a single dose of 40 mg/kg of PZQ significantly reduced the infection prevalence and intensity in all villages of the study area, confirming the efficacy of PZQ in the treatment of urinary schistosomiasis. The CR and ERRs obtained are higher than those observed in previous studies conducted in seasonal *S. haematobium* transmission foci [37] despite that the fact that the treatment was done during the transmission period due to the none accessibility of PZQ after baseline survey in June and July.

Indeed, to better assess the impact of treatment, PZQ should be administered during the low or non-transmission period. However, this does not affect the treatment outcome, since in Niakhar the transmission of *S. haematobium* is strictly seasonal and occurs from July to November; hence the adult worms from the previous transmission periods were exposed to the August 2011 PZQ treatment. However, the collection of one urine sample per child due to limited resources could be a limit explaining the high CR obtained in this Niakhar study. The examination of two or more urine samples per child on different days and more than filtration should be more appropriate for estimating the CR and ERR because of the day-to-day variation in egg excretion in urine [39].

Five weeks after treatment, eggs were found in 6.3 % of treated children in this study, particularly in the boys group, where the highest pre-treatment GEMC was observed. The same trend was also observed in young Gambians [37]. In this Niakhar study, for each child, the PZQ was given under the supervision of a nurse at the health center; therefore, the probability that these excreted eggs come from non-compliance with PZQ is unlikely. However, egg excretion is very common after treatment with PZQ [15] and *S. haematobium* eggs that have been dead for some time can be excreted some months after the drug administration [40]. Therefore, to fully assess PZQ efficacy, it would more appropriate to determine by hatching the viability of the eggs still being excreted by some individuals.

The treatment period could also be the cause of the presence of eggs in these children. Indeed, an infection could occur between July and August 2011 just before

PZQ administration and when the rainfall and the frequency of transmission sites are high. The PZQ administered during this period is not effective against the immature stages of the parasite infecting the children [41]. These immature forms could reach the adult stage and their eggs can be detected during evaluation of the efficacy of PZQ in September 2011. Therefore, this rate of egg excretion after treatment could be very low or even zero if the treatment was administered during non-transmission period between March and May and the control carried out before July, in addition to the egg viability assessment.

The present study nevertheless shows the difficulty with a single dose of PZQ to cure totally some children in whom the intensity of the infection was very high before treatment [42]. A supplementary dose of PZQ could be necessary to completely cure this category of infected individuals in the Niakhar study area. However, in this strictly seasonal transmission area there was no difference in the CR and ERRs of *S. haematobium* between villages after PZQ treatment. It seems that these parameters were not linked to the intensity of infection in the villages at baseline before administering PZQ. These results are contrary to those observed in highly endemic villages in Côte d'Ivoire where transmission is permanent [43] and indicate a clear association between PZQ efficacy and infection intensity prior to treatment for *S. mansoni* [44].

The use of PZQ always remains a valuable strategy for morbidity prevention and the control of *S. haematobium* transmission. Indeed, prevalence and infection intensity after reinfection decreased significantly compared to the baseline because a low rate of reinfection was observed at the end of the 2011 transmission season in the study village. This low level of reinfection could be explained by a low level of transmission in the study site but also by the fact PZQ treatment considerably reduced children harboring eggs, thus resulting in a decrease of the snails infection [45]. Another factor might be the ecology of the area, which is characterized by a short transmission period and that some children may have the chance of being infected in an interval of one or even two years. Few infections were reported in an area where transmission sites were composed of seasonal rain-fed ponds when PZQ treatment was administered and monitored in the non-transmission period [37]. This is also the case in some transmission foci where populations also use only temporal ponds [18, 43]. These conditions are contrary to what happens in the SRB, where transmission and reinfection of *S. haematobium* and *S. mansoni* occurs throughout the year and prevalence after six-month period following treatment can reach the pretreatment levels, especially for *S. mansoni* [7, 23]. During this study, reinfection is more significant in males than in females. This difference may be due to cultural, behavioral
and social factors that put boys in more contact with water collections than girls [29].

The current results show that the efficacy of PZQ against *S. haematobium* was satisfactory and that treatment has a considerable impact on the morbidity due to eggs and affect the occurrence of reinfection in children surveyed in all the villages studied. This suggests that PZQ mass administration between March and May could be used to significantly reduce child carriers of *S. haematobium* and to control the disease in order to move towards elimination of urinary schistosomiasis in seasonal foci in Senegal.

## Conclusion

The baseline results confirm that urinary schistosomiasis is a public health problem in the Niakhar District. A single dose of 40 mg/kg of PZQ has a significant impact on the prevalence and the intensity of infection. This paper suggest that when transmission is not constant and large-scale as it was in the Senegal River Basin, PZQ shows the expected efficacy and a significant effect on the occurrence of reinfection due to the strict seasonality of transmission. These results provide a basis for possible implementation of a urinary schistosomiasis control program in the district of Niakhar but also in other foci were transmission is only seasonal in Senegal.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

CS, AD, CTB, OTD, IT and BS planned the study design. MS and BS performed field activity. BS performed laboratory work. SNS, OTD, SD and BS have made substantial contributions to analysis and interpretation of data. SD, OTD and BS provided substantial improvement of the manuscript and AD and CS provided scientific supervision of the study. All authors approved the final version of the manuscript.

## Acknowledgements

This study was made possible through support provided by the URMITE-IRD in Senegal. We thank the National Program for the Fight against Schistosomiasis in Senegal for the drug donations and assistance in the treatment. We would like to thank the pupils, their parents, and the staff of the Niakhar health centers. We thank also the investigators of IRD in Niakhar and Paul Senghor for field and technical assistance, respectively.

## Author details

¹Institut de Recherche pour le Développement, UMR 198 (URMITE), Campus International de Hann, IRD, BP 1386, Dakar CP 18524, Sénégal. ²Département de Biologie Animale, Université Cheikh Anta Diop de Dakar, Dakar BP 5005, Senegal. ³UFR Sciences Appliquées et Technologies, Université Gaston Berger de Saint Louis, Saint Louis BP 234, Senegal. ⁴Institut Sénégalais de Recherches Agricoles, ISRA, route des Hydrocarbures, Bel Air, Dakar, Senegal. ⁵Programme national de lutte contre les bilharziose s et les géo-helminthiases, ministère de la santé et de l'action sociale, Dakar, Sénégal.

Received: 19 May 2015 Accepted: 1 July 2015

Published online: 10 July 2015

## References

1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411–25.

2. Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, Ornbjerg N, et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology. 2009;136:1859–74.

3. Hotez P, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357(10):1018–27.

4. WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. Geneva: World Health Organisation; 2002.

5. Doumenge JP, Mott K, Cheung C, Villenave D, Chapuis O, Perrin MF, et al. Atlas of the global distribution of schistosomiasis. Bordeaux: Presses Universities de Bordeaux; 1987.

6. Grysels B, Katja P, Jan C, Luc K. Human schistosomiasis. Lancet Infect Dis. 2006;368:1106–18.

7. Webster BL, Diaw OT, Seye MM, Faye DS, Stothard JR, Sousa-Figueiredo JC, et al. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop. 2013;128(2):292–302.

8. Hira PR. Studies on the capability of the snail transmitting urinary schistosomiasis in Western Nigeria to survive dry conditions. West Afr Med J Niger Pract. 1968;17(5):153–60.

9. Diaw OT, Seye M, Sarr Y. Résistance à la sécheresse de mollusques du genre Bulinus vecteurs de trématodoses humaines et animales au Sénégal. II. Étude dans les conditions naturelles en zone Nord-soudanienne. Ecologie et résistance à la sécheresse de Bulinus umbilicatus et Bulinus senegalensis. Revue Elev Méd Vét Pays trop. 1989;42(2):177–87.

10. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programeam managers. Geneva: World Health Organization; 2006.

11. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology. 2009;136:1719–30.

12. Stelma F, Talla I, Sow S, Kongs A, Niang M, Polman K, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:167–70.

13. Wang W, Wang L, Liang YS. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111:1871–7.

14. Ahmed AM, Abbas H, Mansour FA, Gasim Gl, Adam I. Schistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantel. Parasites Vectors. 2012;5:108.

15. Webster BL, DO T, SM M, Faye DS, Stothard JR, Sousa Figueiredo JC, et al. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and reinfection patterns. Acta Trop. 2013;28:292–302.

16. Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, et al. Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the anthelminthic drug praziquantel. PLoS Negl Trop Dis. 2011;5(5):e1143.

17. Augusto G, Magnussen P, Kristensen TK, Appleton CC, Vennervald J. The influence of transmission season on parasitological cure rates and intensity of infection after praziquantel treatment of Schistosoma haematobium infected schoolchildren in Mozambique. Parasitology. 2009;136:1771–9.

18. Garba A, Campagne G, Tassie JM, Barkire A, Vera C, Sellin B, et al. Long-term impact of a mass treatment by praziquantel on morbidity due to Schistosoma haematobium in two hyperendemic villages of Niger. Bull Soc Pathol Exot. 2004;97(1):7–11.

19. Ernould JC. Epidémiologie des schistosomoses humaines dans le delta du fleuve Sénégal : phénomène récent de compétition entre Schistosoma haematobium Sambon, 1907 et S. mansoni (Bilharz, 1852) [PhD thesis]. Université de Paris 12: Val de Marne, Médecine Parasitologie, 1996, 602 p.

20. Diaw OT, Seye M, Sarr Y. Épidémiologie des trématodoses du bétail dans la région de Kolda, Casamance Sénégal. Rev El Méd vét Pays trop. 1988;41(3):257–64.

21. Sy I, Diawara L, Ngabo D, Barbier D, Dreyfuss G, Georges P. Schistosomiasis in school children in the Bandafassi region of East Senegal. Med Trop. 2008;68(3):267–71.

22. De Clercq D, Vercruysse J, Picquet M, Shaw DJ, Diop M, Ly A, et al. The epidemiology of a recent focus of mixed Schistosoma haematobium and Schistosoma mansoni infections around the 'Lac de Guiers' in the Senegal River Basin. Senegal TM IH. 1999;4(8):544–50.
23. De Clercq D, Hanne C, Vercruysse J. Selected chemotherapy and seasonally transmitted Schistosoma haematobium infections in the middle valley of the Senegal River Basin. Trans R Soc Trop Med Hyg. 2000;94(2):198-9.

24. Talla I, Kongs A, Verle P, Belot J, Sarr S, Coll AM. Outbreak of intestinal schistosomiasis in the Senegal River Basin. Ann Soc Belg Med Trop. 1990;70(3):173-80.

25. Sokolow SH, Lafferty KD, Kuris AM. Regulation of laboratory populations of snails (Biomphalaria and Bulinus spp.) by river prawns, Macrobrachium spp. (Decapoda, Palaemonidae): implications for control of schistosomiasis. Acta Trop. 2014;132:64-74.

26. Savaya Alkalay A, Rosen O, Sokolow SH, Faye YP, Faye DS, Afalzo ED, et al. The prawn Macrobrachium vollenhovenii in the Senegal River basin: towards sustainable restocking of all-male populations for biological control of schistosomiasis. PLoS Negl Trop Dis. 2014;8(8):e3060.

27. Ndir O. Situation des Schistosomoses au Sénégal. In: Chippaux JP, editor. La lutte contre les Schistosomoses en Afrique de l'Ouest. Paris: IRD; 2000. p. 225-36.

28. Seck I, Faye A, Gning B, Tal-Dia A. La prévalence de la bilharziose urinaire et ses facteurs de risque en milieu scolaire rural à Fatick au Sénégal. Med Afr Noire. 2007;54:125-31.

29. Senghor B, Diallo A, Sylla SN, Doucoure S, Ndiath MO, Gaayeb L, et al. Prevalence and intensity of urinary schistosomiasis among school children in the district of Niakhar, region of Fatick, Senegal. *Parasites Vectors*. 2014;7:5.

30. Levi P, Adyamagbo A. Tableau de bord des principaux indicateurs sociodémographiques dans la zone de Niakhar (Sénégal). Dakar: IRD; 2003.

31. Delaunay V, Douillot L, Diallo A, Dione D, Trape JF, Medianikov O, et al. Profile: the Niakhar health and demographic surveillance system. Int J Epidemiol. 2013;42(4):1002-11.

32. Plouvier S, Leroy JC, Colette J. A propos d'une technique simple de filtration des urines dans le diagnostic de la bilharziose urinaire en enquête de masse. Med Trop. 1975;35:229-30.

33. WHO. Report of the who informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24months. Geneva: World Health Organization; 2002.

34. Kirkwood BR, Sterne JA. Essential medical statistics. 2nd Edition ed. Oxford: Wiley-Blackwell; 2003.

35. Tchuem Tchuenté LA, Sabine C, Momoa J, Stothard R, Rollinson D. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. Acta Trop. 2013;128:275-83.

36. Jordan P, Webbe G, Sturrock F. Human Schistosomiasis. Wallingford: CAB International; 1993.

37. Wilkins HA, Blumenthal UJ, Hagan P, Hayes RJ, Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. Trans R Soc Trop Med Hyg. 1987;81(1):29-35.

38. Betterton C, Ndifon GT, Tan RM. Schistosomiasis in Kano State, Nigeria. II. Field studies on aestivation in Bulinus rohlfesi (Clessin) and B. globosus (Morelet) and their susceptibility to local strains of Schistosoma haematobium (Bilharz). Ann Trop Med Parasitol. 1988;82(6):571-9.

39. Engels D, Sinzinkayo E, Gryseels B. Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. Am J Trop Med Hyg. 1996;54(4):319-24.

40. McMahon JE, Kolstrup N. Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J. 1979;2(6202):1396-9.

41. Magnussen P. Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years' experiences. Acta Trop. 2003;86(2-3):243-54.

42. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis. 2011;5(9):e1321.

43. N'Goran EK, Utzinger J, N'Guessan AN, Mûller I, Zamblé K, Lohourignon KL, et al. Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire. TM IH. 2001;6(10):817-25.

44. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. TM IH. 2000;5(11):771-8.

45. Stothard JR, Ameri H, Khamis IS, Blair L, Nyandindi US, Kane RA, et al. Parasitological and malacological surveys reveal urogenital schistosomiasis on Mafia Island, Tanzania to be an imported infection. Acta Trop. 2013;128(2):326-33.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central